Figure 4.

Orelabrutinib enhanced apoptosis of tumor cells induced by rituximab

(A and B) B cell lymphoma cells (TMD8 and Z138) were treated with increasing concentration of ibrutinib or Orel for 48 h; after then, cells were stained with PI and Annexin V-FITC. Statistical analysis was performed using one-way ANOVA. Values from three independent experiments are presented as percentages of vehicle in mean ± SD. ∗p < 0.05 and ∗∗p < 0.01 compared among these groups. (C) NK cells isolated from healthy volunteers were pretreated with Orel or ibrutinib at 1 μM for 1 h, TMD8 and Z138 were transduced with firefly GFP, and then rituximab or PBS was added to wells and co-incubated with pretreated NK cells. After incubation at 37°C for 48 h, cells were stained with PI and Annexin-633. GFP⁺ cells were gated to analyze tumor apoptosis by flow cytometer. The column graph represents the percent of cell apoptosis for each group. Statistical analysis was performed using one-way ANOVA. Values of three biologically independent tests are presented as percentages of vehicle in mean ± SD. ∗p < 0.05 compared with vehicle group; ∗∗p < 0.01 compared with control group. #p < 0.05 compared with rituximab group; ##p < 0.01 compared with rituximab group.